BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20031753)

  • 1. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.
    Wessely R; Koppara T; Bradaric C; Vorpahl M; Braun S; Schulz S; Mehilli J; Schömig A; Kastrati A;
    Circ Cardiovasc Interv; 2009 Oct; 2(5):430-7. PubMed ID: 20031753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
    Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures.
    Laskey W; Aspelin P; Davidson C; Rudnick M; Aubry P; Kumar S; Gietzen F; Wiemer M;
    Am Heart J; 2009 Nov; 158(5):822-828.e3. PubMed ID: 19853704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.
    Thomsen HS; Morcos SK; Erley CM; Grazioli L; Bonomo L; Ni Z; Romano L;
    Invest Radiol; 2008 Mar; 43(3):170-8. PubMed ID: 18301313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
    Solomon RJ; Natarajan MK; Doucet S; Sharma SK; Staniloae CS; Katholi RE; Gelormini JL; Labinaz M; Moreyra AE;
    Circulation; 2007 Jun; 115(25):3189-96. PubMed ID: 17562951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media.
    Alexopoulos E; Spargias K; Kyrzopoulos S; Manginas A; Pavlides G; Voudris V; Lerakis S; McLean DS; Cokkinos DV
    Am J Med Sci; 2010 Jan; 339(1):25-30. PubMed ID: 19996728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
    Heinrich MC; Häberle L; Müller V; Bautz W; Uder M
    Radiology; 2009 Jan; 250(1):68-86. PubMed ID: 19092091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty.
    Song T; Song M; Ge Z; Li Y; Shi P; Sun M
    J Interv Cardiol; 2017 Jun; 30(3):281-285. PubMed ID: 28421628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxic effects in high-risk patients undergoing angiography.
    Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Berg KJ;
    N Engl J Med; 2003 Feb; 348(6):491-9. PubMed ID: 12571256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
    Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
    Chen Y; Hu S; Liu Y; Zhao R; Wang L; Fu G; He Q; Su X; Zheng Y; Qi X; Liu H; Wang J; Gao W; Wang M; Liu S; Zheng X; He B; Yang P; Zhou S; Gao C; Qiu C
    EuroIntervention; 2012 Nov; 8(7):830-8. PubMed ID: 23045301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study.
    Giustino G; Baber U; Mastoris I; Vlachojannis GJ; Yu J; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Nikolsky E; Wong SC; Theodoropoulos KN; Dangas GD; Mehran R
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):703-9. PubMed ID: 26481591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of non-ionic iodinated contrast media on patient heart rate and pressures during intra-cardiac or intra-arterial injection.
    Schmid I; Didier D; Pfammatter T; Garachemani A; Fleisch M; Kirchin MA; Meier B
    Int J Cardiol; 2007 Jun; 118(3):389-96. PubMed ID: 17376548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients.
    Feldkamp T; Baumgart D; Elsner M; Herget-Rosenthal S; Pietruck F; Erbel R; Philipp T; Kribben A
    Clin Nephrol; 2006 Nov; 66(5):322-30. PubMed ID: 17140161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty.
    Hernández F; Mora L; García-Tejada J; Velázquez M; Gómez-Blázquez I; Bastante T; Albarrán A; Andreu J; Tascón J
    Rev Esp Cardiol; 2009 Dec; 62(12):1373-80. PubMed ID: 20038403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter comparison of high concentration contrast agent iomeprol-400 with iso-osmolar iodixanol-320: contrast enhancement and heart rate variation in coronary dual-source computed tomographic angiography.
    Becker CR; Vanzulli A; Fink C; de Faveri D; Fedeli S; Dore R; Biondetti P; Kuettner A; Krix M; Ascenti G
    Invest Radiol; 2011 Jul; 46(7):457-64. PubMed ID: 21577124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.